Biocartis (Group)

https://www.biocartis.com

Twitter: @Biocartis_

Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis' ambition is to establish a new gold standard in diagnostic testing. Biocartis provides innovative research and diagnostic systems with multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 140 people. The company has raised in total EUR 125 million in equity. *

	Start	2007-01-01 established
	Industry	molecular diagnostics
	Industry 2	cancer test
	Person	Verrelst, Herman (Biocartis 201709– CEO before Agilent + Cartagenia + Medicim + Data4s)
	Person 2	Welten, Ewoud (Biocartis 201607 CFO)

	Region	Mechelen
	Country	Belgium
	Street	11 B3 Gen. De Wittelaan
	City	2800 Mechelen
	Tel	+32-15-632-600
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2018-12-31)
	Currency	EUR
	Annual sales	37,732,000 (operating income, consolidated (2019) 2019-12-31)
	Profit	-64,068,000 (2019-12-31)
	Cash	178,725,000 (2019-12-31)

		* Document for ï¿½About Sectionï¿½: Biocartis S.A.. (12/5/12). "Press Release: Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform". Lausanne.

		Record changed: 2020-05-17